H.A. Chaudri

1.1k total citations
12 papers, 805 citations indexed

About

H.A. Chaudri is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, H.A. Chaudri has authored 12 papers receiving a total of 805 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Pharmacology. Recurrent topics in H.A. Chaudri's work include Estrogen and related hormone effects (7 papers), Advanced Breast Cancer Therapies (3 papers) and Inflammatory mediators and NSAID effects (2 papers). H.A. Chaudri is often cited by papers focused on Estrogen and related hormone effects (7 papers), Advanced Breast Cancer Therapies (3 papers) and Inflammatory mediators and NSAID effects (2 papers). H.A. Chaudri collaborates with scholars based in Switzerland, United States and Belgium. H.A. Chaudri's co-authors include Ulrike Hornberger, G. Gardin, Lawrence Panasci, P Trunet, A. Gudgeon, A. Fornasiero, Geoffrey Falkson, Myfanwy Morgan, W. Hoffmann and Robert Leonard and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Annals of the Rheumatic Diseases.

In The Last Decade

H.A. Chaudri

12 papers receiving 737 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H.A. Chaudri Switzerland	9	595	405	387	191	93	12	805
Ulrike Hornberger Switzerland	4	445 0.7×	292 0.7×	298 0.8×	144 0.8×	64 0.7×	4	580
M. Lassus Switzerland	12	671 1.1×	659 1.6×	720 1.9×	277 1.5×	197 2.1×	20	1.3k
T Tjabbes Netherlands	6	408 0.7×	291 0.7×	289 0.7×	142 0.7×	68 0.7×	12	617
G. Gademann Germany	5	517 0.9×	395 1.0×	442 1.1×	129 0.7×	61 0.7×	14	733
M. Gershanovich Russia	9	446 0.7×	324 0.8×	322 0.8×	139 0.7×	70 0.8×	11	599
D.J. DeFriend United Kingdom	7	631 1.1×	187 0.5×	376 1.0×	150 0.8×	257 2.8×	17	812
William N. Harwin United States	7	535 0.9×	395 1.0×	488 1.3×	259 1.4×	129 1.4×	21	856
M. Azab United Kingdom	6	390 0.7×	303 0.7×	547 1.4×	228 1.2×	156 1.7×	7	845
Pamela Guglielmini Italy	13	595 1.0×	468 1.2×	577 1.5×	166 0.9×	148 1.6×	24	1.0k
M. Rinaldini Italy	6	501 0.8×	401 1.0×	406 1.0×	130 0.7×	60 0.6×	9	664

Countries citing papers authored by H.A. Chaudri

Since Specialization

Citations

This map shows the geographic impact of H.A. Chaudri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.A. Chaudri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.A. Chaudri more than expected).

Fields of papers citing papers by H.A. Chaudri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.A. Chaudri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.A. Chaudri. The network helps show where H.A. Chaudri may publish in the future.

Co-authorship network of co-authors of H.A. Chaudri

This figure shows the co-authorship network connecting the top 25 collaborators of H.A. Chaudri. A scholar is included among the top collaborators of H.A. Chaudri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.A. Chaudri. H.A. Chaudri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Gershanovich, M., H.A. Chaudri, H. Lurie, et al.. (1998). Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annals of Oncology. 9(6). 639–645. 206 indexed citations

Dombernowsky, P, I E Smith, Geoffrey Falkson, et al.. (1998). Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.. Journal of Clinical Oncology. 16(2). 453–461. 473 indexed citations

Gardin, G., A. Fornasiero, Gilles Romieu, et al.. (1998). Long duration of response with letrozole 2.5 mg (Femara®) in two trials in postmenopausal women with advanced breast cancer after anti-estrogen therapy. European Journal of Cancer. 34. S13–S14. 2 indexed citations

Trunet, Patrick, et al.. (1997). Clinical use of aromatase inhibitors in the treatment of advanced breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 61(3-6). 241–245. 12 indexed citations

Trunet, Patrick, Ajay S. Bhatnagar, H.A. Chaudri, & Ulrike Hornberger. (1996). Letrozole (CGS 20267), A New Oral Aromatase Inhibitor for the Treatment of Advanced Breast Cancer in Postmenopausal Patients. Acta Oncologica. 35(sup5). 15–18. 19 indexed citations

Smith, I. E., Geoffrey Falkson, Renaud Léonard, et al.. (1996). PP-8-3 Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA). European Journal of Cancer. 32. 49–49. 11 indexed citations

Trunet, P, et al.. (1990). Phase I study in healthy male volunteers with the non-steroidal aromatase inhibitor CGS 20267. European Journal of Cancer and Clinical Oncology. 26(2). 173–173. 3 indexed citations

Frost, Heiner, James L. Murray, H.A. Chaudri, & Jo Van Damme. (1990). Interleukin-6 induction by a muramyltripeptide derivative in cancer patients.. PubMed. 9(2). 160–6. 18 indexed citations

Chaudri, H.A., et al.. (1979). The value and results of long-term studies with diclofenac sodium (Voltarol).. PubMed. Suppl 2. 100–15. 9 indexed citations

10.

Chaudri, H.A., et al.. (1979). How long should long be? Long-term trials in rheumatic diseases.. Annals of the Rheumatic Diseases. 38(2). 155–160. 4 indexed citations

11.

Chaudri, H.A., et al.. (1978). Report on a Long-Term Tolerability Study of Up to Two Years with Diclofenac Sodium (Voltaren). Scandinavian Journal of Rheumatology. 7(sup22). 86–96. 36 indexed citations

12.

Chaudri, H.A., et al.. (1975). A Methodological Study of Some Factors Influencing the Reporting of Symptoms. The Journal of Clinical Pharmacology. 15(7). 496–505. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact